Rani Therapeutics Holdings, Inc. - רווח למניה לשנה מתגלגלת RANI

Rani Therapeutics is implementing the RaniPill robotic capsule to replace injections for diabetes. The relative EPS YoY TTM growth rate captures efficiency dynamics, with the indicator level standing at 77.00. Unique patents and strict FDA control serve as a moat for the business. The company is currently scaling partnerships with pharma behemoths and conducting clinical trials to ensure long-term development.
Rani Therapeutics - פילוחים אנליטיים ומדדי מפתח (RANI)

This indicator measures the annual change in net income per share over the last twelve months, allowing for an assessment of business scaling rates and return on investment efficiency. By analyzing the EPS TTM YoY growth metric, an investor can see the impact of the "robotic pill" success and partnerships with pharma behemoths on the actual financial return on capital for Rani Therapeutics (RANI).